Roflumilast Cream 0.15% + Vehicle Cream
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis Eczema
Conditions
Atopic Dermatitis Eczema
Trial Timeline
Jan 27, 2021 โ Aug 30, 2022
NCT ID
NCT04773587About Roflumilast Cream 0.15% + Vehicle Cream
Roflumilast Cream 0.15% + Vehicle Cream is a phase 3 stage product being developed by Arcutis Biotherapeutics for Atopic Dermatitis Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT04773587. Target conditions include Atopic Dermatitis Eczema.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04773587 | Phase 3 | Completed |
Competing Products
20 competing products in Atopic Dermatitis Eczema